Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Mallinckrodt
AstraZeneca
Express Scripts
McKesson

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GTS-21

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for GTS-21?

GTS-21 is an investigational drug.

There have been 8 clinical trials for GTS-21. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Tourette Syndrome, Syndrome, and Schizophrenia. The leading clinical trial sponsors are CoMentis, China Medical University Hospital, and Children's Hospital Medical Center, Cincinnati.

There are eighteen US patents protecting this investigational drug and ninety-nine international patents.

Recent Clinical Trials for GTS-21
TitleSponsorPhase
Selective Microbiota Transplantation for Tourette's SyndromeFaming ZhangPhase 1/Phase 2
Evaluating the Efficacy and Safety of Yi-Gan San in Children and Adolescents With Tourette's DisorderChina Medical University HospitalPhase 2
Effects of GTS-21 on Smoking Behavior and Neurocognitive FunctionsUniversity of FloridaPhase 2

See all GTS-21 clinical trials

Clinical Trial Summary for GTS-21

Top disease conditions for GTS-21
Top clinical trial sponsors for GTS-21

See all GTS-21 clinical trials

US Patents for GTS-21

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GTS-21   Start Trial Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Inhibition of inflammation using .alpha. 7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Treatment of inflammation using .alpha.7 receptor-binding cholinergic agonists The Feinstein Institute for Medical Research (Manhasset, NY)   Start Trial
GTS-21   Start Trial Amide derivatives as positive allosteric modulators and methods of use thereof Abbott Laboratories (Abbott Park, IL)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
McKesson
Colorcon
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.